Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
June 02, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
June 01, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19
May 27, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
May 01, 2020 06:00 ET
|
Annovis Bio Inc.
BERWYN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
April 30, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
April 23, 2020 07:00 ET
|
Annovis Bio Inc.
BERWYN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
April 13, 2020 17:30 ET
|
Annovis Bio Inc.
BERWYN, Pa., April 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
February 27, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other...
Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
February 20, 2020 07:00 ET
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...
Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
February 13, 2020 11:40 ET
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative...